• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Advocacy Toolkit

What is advocacy?

Advocacy is the deliberate process of influencing those who make policy decisions.

In the health, disability, and social care sector, advocacy aims to support or encourage an activity that helps people living with ALS/MND and their caregivers secure access to health and supportive care that best meets their changing and progressing needs.

Advocacy and influencing at a national level is central to the mission of many ALS/MND associations around the world. Advocacy is a means through which ALS/MND associations ensure that people living with ALS/MND have access to the best possible care within their legal, health, and supportive care systems.

This resource is designed to help you and your association, whether you are just starting an advocacy program or looking to expand an existing one. It also gives emerging ALS/MND associations tools they can use to begin engaging in advocacy at the local, regional, national, and international levels.

On this page

Types of advocacy  │  What advocacy can do  │  Systemic advocacy  │  Common areas  │  Tips for successful advocacy

Types of advocacy

There are three main types of advocacy used by ALS/MND associations and advocates around the world: individual advocacy, systemic advocacy, and collaborative advocacy.

Individual advocacy

Individual advocacy focuses on changing the situation of one person, to protect their rights or to improve individual services.

There are two common forms of individual advocacy:

  1. Informal advocacy is undertaken by individuals, their relatives, and friends.Many people living with ALS/MND and their families have engaged in valuable informal advocacy, but managing ALS/MND can leave little time for the extra effort involved.
  2. Voluntary or nonprofit community-based organizations advocate for individuals.Many ALS/MND associations engage in this type of advocacy. Associations may employ support staff who help individuals living with ALS/MND and their families access care and support services locally as needs arise or change. This is an important means of advocacy because care systems are often very complex and difficult for individuals to navigate.

    This advocacy also involves educating care providers about the needs of people living with ALS/MND, to promote access to timely and coordinated multidisciplinary care.

Systemic advocacy

Systemic advocacy works to change the situations of a whole group of people who share a similar problem, or to change a service system. It can benefit many people, and it also strives to prevent problems before they occur.

Systemic advocacy encourages changes to laws, to government and service provider policies, and to community attitudes.

ALS/MND associations may undertake systemic advocacy at the local level (for example, state, province, region, or territory) or at the national level within their countries.

Collaborative advocacy

The number of people living with ALS/MND is relatively small, which makes influencing harder. There is power in numbers.

For particular issues, ALS/MND associations may consider joint advocacy with other groups that have the same or similar needs. These organizations include:

  • neurological groups
  • neurodegenerative or neuromuscular disease groups
  • disability groups
  • chronic disease or rare disease alliances
  • palliative care associations
  • caregiver associations

What does advocacy do for people living with ALS/MND?

Advocacy can:

  • raise awareness and understanding of ALS/MND and the needs of people living with ALS/MND, their families, and their caregivers
  • promote research into ALS/MND
  • promote positive changes to structures and policies that benefit people living with ALS/MND
  • help people living with ALS/MND and their families access more resources and better care
  • help professionals who provide services to people living with ALS/MND and their families gain access to resources and funding
  • help people living with ALS/MND and their families access vital support services and hold those services accountable, ensuring transparency in their actions and decisions
  • help people living with ALS/MND and their families have control over their situation

What does systemic advocacy require?

Systemic advocacy works to change service systems, policies, or laws, so it requires a long-term, sustained effort. It also requires:

  • knowledge of how systems, departments, and services work, especially government and health and supportive care departments
  • an understanding of advocacy processes and procedures
  • taking opportunities and creating them
  • a sense of urgency
  • doing more than what is routinely done
  • challenging the community
  • engaging with media

Understand how decisions are made

Above all, advocacy requires that ALS/MND associations know and understand the basic functions of government and how health, social, and supportive care is structured in their country. Answering these questions will help you get started:

  • How is a law made?
  • What are the branches of government, and what is each branch responsible for? Whom should you be advocating to?
  • Who is responsible for allocating resources, and how are these decisions made?
  • What are the current government’s policies on care and support that affect people living with ALS/MND and their families?
  • How do people find their representatives and contact them?

The answers to these questions may differ depending on whether you are working at a local or national level.

Common areas of advocacy

For Alliance member associations, past and current areas for advocacy may include:

  • improved clinical care for people living with ALS/MND within a given health care system, including:
    • access to multidisciplinary care
    • access to durable medical equipment
  • improved support services for people living with ALS/MND and their families, including:
    • access to aids and equipment
    • home care
    • disability or aged care support
    • respite care
  • financial support for people living with ALS/MND and their families
  • ALS/MND research funding
  • increased public awareness and understanding of ALS/MND through official recognition of the disease or related issues

Tips for successful advocacy

  • Have clear, realistic goals. Be as specific as you can. Consider developing short-term and long-term goals and dividing big, general goals into achievable steps.
  • Be strategic and efficient. Try to talk to the right person at the right time to move your policy forward.
  • Develop a campaign or call to action that focuses on the policy you want to change.
  • Try different tactics. Ways to contact policymakers include:
    • arranging meetings with relevant politicians and government departments in their offices
    • engaging with the party in power as well as the opposition
    • inviting politicians to visit your association or clinic
    • writing letters and making phone calls
    • using social and traditional media to persuade politicians to champion your call to action
    • attending town hall meetings or other public events to educate policymakers
  • Encourage grassroots advocates.
    • Identify grassroots advocates: people living with ALS/MND who support your association and are willing to meet, write letters, email, or call their elected representatives, using a script you provide.
    • Give your grassroots advocates a list of ministers, opposition spokespeople, and other elected representatives to contact.
  • Have facts and figures prepared. Find and know the relevant statistics. If possible, conduct surveys or research to produce more figures, such as the average cost of living with ALS/MND for one year in your country, or the average life expectancy of someone living with ALS/MND in your country. Present facts and figures in an organized, concise way, often through printed handouts or fact sheets.
  • Develop a media and communications plan. Think about how you will communicate your advocacy campaign and engage the public to support your goals.
  • Share personal stories. A personal story from someone living with ALS/MND who needs help is often the most persuasive argument. An association should always get permission and support from the individual before sharing their story.

Advocacy by ALS/MND associations promotes recognition of the rights and needs of people living with ALS/MND and ensures that they have a voice and that it is heard.

Related information

Fundamental Rights for People with ALS/MND and Caregivers  │  Equitable Access to Therapies on a Global Scale

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Daniel Hare, USA

    Daniel Hare, USA

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • David Watson, Scotland

    David Watson, Scotland

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Claudia Cominetti, Italy

    Claudia Cominetti, Italy

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Maria Santos Garcia Tellez, Mexico

    Maria Santos Garcia Tellez, Mexico

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Mirca Bersani, Italy

    Mirca Bersani, Italy
    MircaBersani

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Bayley, Australia

    Bayley, Australia

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Alex, Argentina

    Alex, Argentina

  • Liam Dwyer, England

    Liam Dwyer, England

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Olga, Argentina

    Olga, Argentina

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Susan Keldani, USA

    Susan Keldani, USA

  • Camilla Heiberg Freiberg, Denmark

    Camilla Heiberg Freiberg, Denmark

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Anna Barrow, UK

    Anna Barrow, UK

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Paul Launer, USA

    Paul Launer, USA

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Zabun Nassar, England

    Zabun Nassar, England

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Lombana, Spain

    Lombana, Spain

  • Glen Elison, USA

    Glen Elison, USA

  • Ali Var, Turkey

    Ali Var, Turkey

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Denis Blais, Canada

    Denis Blais, Canada

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login